3963 MAPLE AVENUE, DALLAS, TX
RSM US LLP Appointed As Independent Auditor; Deloitte Dismissed
Financial Results, Press Release
Termination of License Agreement with ImmuneOnco - Axion Bio, Inc.
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Other Events
Shareholder votes
Phase 2 Trial of IMM2510/AXN-2510 in NSCLC on Track for Q3 2025 Enrollment
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Definitive Revised Proxy Statement
Submission Upload
Correspondence